These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27460820)

  • 1. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
    Nguyen L; Fifis T; Christophi C
    BMC Cancer; 2016 Jul; 16():533. PubMed ID: 27460820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.
    Fifis T; Nguyen L; Malcontenti-Wilson C; Chan LS; Nunes Costa PL; Daruwalla J; Nikfarjam M; Muralidharan V; Waltham M; Thompson EW; Christophi C
    Cancer Med; 2013 Oct; 2(5):595-610. PubMed ID: 24403226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.
    Nguyen L; Fifis T; Malcontenti-Wilson C; Chan LS; Costa PN; Nikfarjam M; Muralidharan V; Christophi C
    BMC Cancer; 2012 Nov; 12():522. PubMed ID: 23153292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
    Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
    Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model.
    Malcontenti-Wilson C; Chan L; Nikfarjam M; Muralidharan V; Christophi C
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e96-e104. PubMed ID: 17559382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in vascular architecture and permeability following OXi4503 treatment.
    Chan LS; Malcontenti-Wilson C; Muralidharan V; Christophi C
    Anticancer Drugs; 2008 Jan; 19(1):17-22. PubMed ID: 18043126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis.
    Chan LS; Malcontenti-Wilson C; Muralidharan V; Christophi C
    Anticancer Res; 2007; 27(4B):2317-23. PubMed ID: 17695520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemia regression by vascular disruption and antiangiogenic therapy.
    Madlambayan GJ; Meacham AM; Hosaka K; Mir S; Jorgensen M; Scott EW; Siemann DW; Cogle CR
    Blood; 2010 Sep; 116(9):1539-47. PubMed ID: 20472832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
    Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
    Dalal S; Burchill SA
    Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
    J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
    Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
    Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic seeding of human colon cancer cell clusters expressing the hybrid epithelial/mesenchymal state.
    Mizukoshi K; Okazawa Y; Haeno H; Koyama Y; Sulidan K; Komiyama H; Saeki H; Ohtsuji N; Ito Y; Kojima Y; Goto M; Habu S; Hino O; Sakamoto K; Orimo A
    Int J Cancer; 2020 May; 146(9):2547-2562. PubMed ID: 31506938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
    Robert F; Sandler A; Schiller JH; Liu G; Harper K; Verkh L; Huang X; Ilagan J; Tye L; Chao R; Traynor AM
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):669-80. PubMed ID: 20043166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
    Salmon HW; Siemann DW
    Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.